Novo Nordisk wins key South Africa ruling, shares extend obesity-drug lead

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-23, 07:59.

Novo Nordisk (DK0062498333) strengthens its position in the obesity and diabetes market after a South African court backed its attempt to block unauthorized semaglutide copies, as reported by Reuters. The stock is part of the OMX Copenhagen 25 and its ADRs trade on the NYSE.

What Reuters reports on the ruling

According to a Reuters report on 22 June 2026, a court in Gauteng, South Africa, granted Novo Nordisk an order to stop local company iDexis from selling a semaglutide product that Novo argued infringed its Ozempic rights. The decision covers compounded versions meant to mimic the GLP-1 active ingredient.

Reuters states that the court accepted Novo Nordisk’s argument that the iDexis product unlawfully used its registered trademarks and formulation linked to Ozempic, a blockbuster diabetes drug also used off-label for weight loss. The ruling reinforces Novo’s intellectual-property stance in a market where affordability and generic pressure are high.

Operational backdrop and analyst focus

Beyond South Africa, Novo Nordisk’s GLP-1 franchise remains central to global earnings expectations, with Ozempic and the obesity drug Wegovy driving much of the company’s growth compared with peers such as Eli Lilly. MarketScreener data show the B share closing at 299.95 Danish kroner on 22 June 2026 on Nasdaq Copenhagen within the OMX Copenhagen 25 benchmark.MarketScreener quote and company overview

Analyst houses, including Bernstein with a Market-Perform stance as of May 2025, continue to highlight both patent protection and manufacturing capacity as key variables for Novo Nordisk’s medium-term margin profile.Bernstein rating summary via finanzen.at The South African court outcome feeds into that narrative of defending exclusivity around semaglutide-based therapies.

The treatments behind the stock

Novo Nordisk generates most of its revenue from diabetes and obesity care, with semaglutide-based brands such as Ozempic for type 2 diabetes and Wegovy for chronic weight management. These GLP-1 therapies complement long-established insulin products in its portfolio.

Where the shares trade today

The Novo Nordisk shares (DK0062498333) last closed on 2026-06-22 at 299.95 Danish kroner on Nasdaq Copenhagen, while the NVO ADRs ended regular NYSE trading at 45.90 US dollars on the same date.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities.